Dialectic Therapeutics (DT) is a biotech start up dedicated to the development of impactful and unique anti-cancer drugs to effectively treat cancers with few to no other options. Founded by three respected cancer scientists and two successful biotech investors, DT is located in Dallas and has research facilities/partners at UT Health in San Antonio (UTHSA) and the University of Florida. DT’s lead candidate, DT2216, is a unique programmed protein degradation compound that selectively induces cancer cells to degrade BCL-XL, stimulating the cells to commit suicide on their own, or become more susceptible to chemotherapy. Cancer cells are less likely to develop resistance to DT2216 because of i...

Read More

Dialectic Therapeutics (DT) is a biotech start up dedicated to the development of impactful and unique anti-cancer drugs to effectively treat cancers with few to no other options. Founded by three respected cancer scientists and two successful biotech investors, DT is located in Dallas and has research facilities/partners at UT Health in San Antonio (UTHSA) and the University of Florida. DT’s lead candidate, DT2216, is a unique programmed protein degradation compound that selectively induces cancer cells to degrade BCL-XL, stimulating the cells to commit suicide on their own, or become more susceptible to chemotherapy. Cancer cells are less likely to develop resistance to DT2216 because of its unique mechanism of action. Preliminary studies show that DT2216 destroys T-cell lymphoma / T-cell leukemia as a single agent. It is effective against small cell lung cancer and breast cancer when combined with traditional chemotherapy. The toxicity profile is favorable showing only a dose dependent decrease in platelets. This novel approach to cancer therapy will fill a significant need in current cancer treatment regimens. The clinical studies can all be performed at Texas institutions. The work supported by the CPRIT TXCO grant will enable DT to perform clinical phase trials for DT2216 in the treatment of T-cell lymphoma and small cell lung cancer. When successful, we will relieve the suffering of patients with cancer, give them hope and prolong their productive lives.

Read Less